4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics completed enrollment for the 4FRONT-2 global Phase 3 trial of 4D-150 in wet AMD approximately four months ahead of schedule and with over-enrollment anticipated at more than 500 patients. The 4FRONT-2 trial is a randomized, double-masked study comparing 4D-150 to aflibercept, with 52-week topline data expected in the second half of 2027. The company also noted that 4FRONT-1 topline data is anticipated in the first half of 2027.
Key figures
- Drug Name
- 4D-150
- Phase Of Trial
- Phase 3
- 4front1 data readout
- H1 2027
- 4front2 data readout
- H2 2027
- Anticipated enrollment
- >500
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.